New Treatment Combo for Non-Hodgkins Lymphoma
Roswell Park Comprehensive Cancer CenterA multi-institutional clinical study led by Roswell Park Cancer Institute has demonstrated the safety and effectiveness of a chemoimmunotherapy treatment for patients with non-Hodgkin's lymphoma. The overall response rate was 95% for patients who received treatment with a combination of Rituxan, a monoclonal antibody, and the systemic standard dose chemotherapy regimen used for this disease.